Ascentage Pharma Group International

NASDAQ:AAPG

Biotechnology

Healthcare
$13.01 +1.78%

+$0.31 today

Market cap
$1.21B
Beta
0.65
P/E (TTM)
-8.9
EPS (TTM)
-$13.29
52W Low $16.92High $48.45

Volume 0.00M

Average 0.01M

AAPG Purchases of Investments

Cash used to buy marketable securities and other investments.

Ascentage Pharma Group InternationalNASDAQ: AAPG

Purchases of Investments · Q4 FY2025 · quarter ended Dec 2025

Purchases of investments grows 885.9% year over year

Q4 FY2025 purchases of investments of CN¥294M (cash outflow) rose 885.9% year over year. Over 3 fiscal years it compounded at +92.6% a year.

Context

  • Purchases of investments amounted to 166.4% of revenue in FY2025, up 134.5 pp from a year earlier.
  • Purchases of investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-CN¥294M— QoQ
Last fiscal yearDec 2025
-CN¥929.14M+197.6% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+885.9%——
1 year+197.6%——
3-year CAGR+92.6%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

CNY · from the cash flow

Latest · FY2025
(929.14M) CNY
Year-over-year change
-197.6%

Purchases of Investments vs competitors

How AAPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +197.6% is the 2nd highest of 8, against a peer median of +19.8%.
  • Purchases of investments amounts to 166.4% of revenue for AAPG, versus a peer median of 32.3%.
AAPG Competitors
Purchases of Investments for AAPG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNGXTango Therapeutics, Inc.LTM Sep 2026$1.05B USD+760.8%+8.2%—
AAPGAscentage Pharma Group InternationalFY2025CN¥929.14M CNY+197.6%+92.6%166.4%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$604.34M USD+4.3%+23.9%86.1%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$545.29M USD-33.6%+33.4%242.1%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$327.5M USD+60.6%——
CCCCC4 Therapeutics, Inc.LTM Mar 2026$242.25M USD+19.8%+1.1%694.9%
IMRXImmuneering CorporationLTM Mar 2026$160.59M USD—+20.9%—
VSTMVerastem, Inc.LTM Mar 2026$16.02M USD——32.3%
NUVBNuvation Bio Inc.LTM Jun 2026$7.46M USD-97.1%-12.0%4.4%
ZLABZai Lab LimitedLTM Jun 2026$0 USD+100.0%-66.3%0.0%
ANLAdlai Nortye Ltd.LTM Jun 2024$0 USD—-29.7%0.0%
Peer median (excluding AAPG) —+19.8%+4.7%32.3%

Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(832.25M)(887.17M)(932.86M)(395.26M)(1.24B)
Depreciation & Amortization28.33M62.92M93.2M93.17M86.48M
Deferred Income Tax00000
Stock-Based Compensation46.97M22.11M31.5M20.92M20.87M
Change in Working Capital(74.91M)104.41M(9.15M)110.97M(143.5M)
Accounts Receivables(53.97M)(388K)(91.54M)62.75M(169.8M)
Inventory(3.93M)(5.52M)(6.72M)9.57M(26.2M)
Accounts Payables024.7M(23.11M)19.52M14.77M
Other Working Capital(17.01M)85.62M112.22M19.13M37.72M
Other Non-Cash Items227.18M43.82M91.23M58.84M98.07M
Operating Cash Flow(604.68M)(653.92M)(726.08M)(111.36M)(1.17B)
Capital Expenditures(436.63M)(236.96M)(56.84M)(24.29M)(27.57M)
Acquisitions (Net)(36.2M)(20M)(20M)(25.52M)(43.34M)
Purchases of Investments(1.78B)(130M)0(312.23M)(929.14M)
Sales of Investments1.79B0000
Other Investing Activities(879K)(31.32M)88.03M(312.23M)0
Investing Cash Flow(466.52M)(384.61M)21.92M(362.04M)(1B)
Debt Repayment548.59M695.87M(13.36M)(145.34M)307.26M
Common Stock Issued1.3B0470.08M533.94M2.3B
Common Stock Repurchased(25.87M)(26.78M)(5.92M)0(9.04M)
Dividends Paid00000
Other Financing Activities(41.97M)(49.83M)(82.05M)(73.83M)(63.04M)
Financing Cash Flow1.78B619.27M368.75M314.77M2.54B
Effect of Forex Changes(23.28M)58.01M27.81M13.68M(63.24M)
Net Change in Cash686.91M(361.25M)(307.59M)(144.95M)302.68M
Free Cash Flow(1.04B)(890.88M)(782.92M)(135.65M)(1.2B)

Ascentage Pharma Group International

NASDAQ:AAPG

Intrinsic Alpha fair value

Locked

Current Price

$13.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.